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Abstract: We are presenting a review of Isolated Systolic Hypertension (ISH) as a cardiovascular risk factor with empha-
sis on the perioperative period.  
Isolated systolic hypertension is associated with aging and is the most frequent subtype (65%) among patients with uncon-
trolled hypertension. ISH is strongly associated with increased risks of cardiac and cerebrovascular events exceeding those 
in comparably aged individuals with diastolic hypertension. Patients with ISH show an increase in left ventricular (LV) 
mass and an increase in the prevalence of left ventricular hypertrophy (LVH). These LV changes increase cardiovascular 
events and frequently lead to diastolic dysfunction (DD). Treatment to reduce elevated systolic blood pressure has been 
shown to reduce the risk of cardiovascular events.  
In the perioperative setting, essential hypertension has not been found to be a significant risk factor for cardiac complica-
tions. Most of the studies were based on the definition of essential hypertension and underpowered in sample size. The 
significance of perioperative ISH, however, is not well studied, partly due to its recognition only fairly recently as a car-
diovascular risk factor in the non-surgical setting, and partly due to the evolving definition of ISH. 
Perioperative cardiac complications remain a significant problem to the healthcare system and to the patient. Although the 
incidence of perioperative cardiac complications is prominent in high-risk patients as defined by the Revised Cardiac Risk 
Index (RCRI), the bulk of the cardiac complications actually occur in low-risk group. Currently, little understanding exists 
on the occurrence of perioperative cardiac complications in low- risk patients. A factor such as ISH, with its known 
pathophysiological changes, is a potential perioperative risk factor.  
We believe ISH is an under-recognized perioperative risk factor and deserves further studying. Our research group has re-
cently been funded by the Heart Stroke Foundation (HSF) to examine ISH as a perioperative risk factor (PROMISE 
Study).  
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I) ISOLATED SYSTOLIC HYPERTENSION AS A 
CARDIOVASCULAR RISK FACTOR 
Background 
  Isolated Systolic Hypertension (ISH) is increasingly rec-
ognized as a cardiovascular risk [1,2]. Several studies have 
shown the strong association between ISH and stroke, car-
diovascular morbidity and mortality [3-5]. Data from Multi-
ple Risk Factor Intervention Trial (MRFIT) demonstrated a 
continuous and graded influence of systolic blood pressure 
(SBP) on coronary heart disease mortality [6]. The study 
found that the greatest number of deaths is seen in patients 
with SBP between 140 and 149 mmHg. However, the high-
est risk of death was found in patients with SBP > 180 
mmHg (Fig. (1)). It also found that SBP was a stronger pre-
dictor of outcome than diastolic blood pressure (DBP). The 
JNC-VII report confirms the close association between ISH 
and cardiovascular events [7]. It also highlights that; SBP 
greater than 140 mm Hg is a more important cardiovascular  
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Fig. (1). The effect of systolic pressure at entry to MRFIT (Multiple 
Risk Factor Intervention Trial) on the relative risk of death because 
of coronary artery disease. The number of excess deaths is calcu-
lated relative to the number of deaths because of coronary artery 
disease that would be expected from the death rate in the baseline 
group, that is those patients with a systolic arterial pressure of less 
than 110 mm Hg.
3 Permission from Oxford University Press (BJA, 
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risk factor than an elevated DBP. The risk of cardiovascular 
disease begins at 115/75 and doubles with each increment of 
20/10 mmHg.  
  The continuous graded influence of high blood pressure 
on cardiovascular disease (CVD) risk was also found in the 
meta-analysis of Prospective Studies Collaboration [8]. It 
involved 61 prospective studies with 1 million participants. 
There were 56,000 vascular deaths related to high blood 
pressure, without any indication of a threshold down to 
115/75 mmHg. The meta-analysis clearly demonstrated the 
higher incidence of ischemic cardiac events and strokes with 
elevated SBP (Figs. (2 & 3)). Masley et al. [9], in a recent 
follow up study, evaluated the association between blood 
pressure and the risk of developing CVD in 4,008 elderly 
patients. The study found that elevated SBP was strongly 
associated with developing future CVD events (P=0.0001); 
the relationship is linear, graded and holds for ages above 
and below 75 years old. It also demonstrated that the fre-
quency of CVD was the lowest with SBP< 120 mmHg while 
elevated DBP didn’t seem to be a major factor for future 
CVD events. Other clinical trials, along with MRFIT, have 
gone a step further to demonstrate that an excess risk of car-
diovascular diseases exists not only in patients with ISH but 
also in pre-hypertensive subjects [10-12]. 
Definition and Classification of ISH: 
  The definition and classification of ISH have undergone 
several iterations. ISH is currently defined as SBP > 140 
mmHg with DBP < 90 mmHg, and not secondary to another 
disorder in individuals aged 18 and older. This is based on 
the average of 2 or more seated BP readings on each of 2 or 
more office visits. The definition is adopted by the Seventh 
Report of the Joint National Committee (JNC-VII) on Pre-
vention, Detection, Evaluation, and Treatment of High Blood 
pressure [7]. The main changes in the classification from the 
previous one (JNC VI) were the development of pre-hyper-
tension as a new classification category and the combining of 
stage 2 and stage 3 hypertension into a single stage 2 cate-
gory (Table 1).  
  Pre-hypertension (SBP of 120 – 130 mmHg) is not a dis-
ease category. Rather it is defined in order to identify indi-
viduals at risk of developing hypertension. They are not can-
didates for treatment but will require health-promoting life-
style modifications to prevent cardiovascular disease. Classi-
fication of the JNC VII does not stratify hypertensive pa-
tients by the presence or absence of risk factors. Also, it does 
not stratify them by the presence or absence of target organ 
damage. Therefore, the JNC VII treatment recommendation 
does not take into consideration if either or both are present. 
However, it recommends that all individuals with stage 1 or 
2 hypertension be treated.  
Epidemiology of ISH 
  The prevalence of ISH increases with age, and it accounts 
for substantial proportion of hypertensive patients. It is the 
most frequent subtype of hypertension in the US [13]. The 
rise in SBP continues throughout life, in contrast to DBP, 
which rises until 50 years old, tends to level off over the next 
decade, and may remain the same or decline later in life [14]. 
All of these studies suggest that age 50 years is a useful cut 
point to dichotomize arbitrarily hypertensive individuals into 
two groups for the purpose of classifying hypertension by sub-
type (Fig. (4)). 
Fig. (2). Ischemic heart disease (IHD) mortality rate in each decade of age versus usual blood pressure at the start of that decade. Source: 
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  In the National Health and Nutrition Examination survey 
(NHANES III), 42.7 million adult Americans were identified 
as hypertensive, which represented 24% of the adjusted adult 
US population [15]. Over 65% of the uncontrolled or un-
treated hypertensive population had ISH. Participants   50 
years of age comprised three fourths of all hypertensive sub-
jects. The older group was predominantly female (58%), 
whereas the younger group was predominantly male (62.5%). 
The predominant hypertensive subtype was ISH (79.8%) in the 
older group (75% stage 1 and 25% stage 2 or higher) and iso-
lated diastolic hypertension (42.8%) in the younger group (98% 
stage 1 and 2% stage 2 or higher). Prevalence of ISH may be 
higher in some populations. A study looked at the character-
istics of ISH in bi-racial Evans County, Georgia, from 1967 
to 69. It found that the prevalence of ISH was higher in fe-
males and in the black population [16]. 
Table 1.  Classification of Hypertension as Identified by Joint National Committee –VII (JNC-VII) [13]
Initial Drug Therapy 
BP Classification  SPB* mmHg 
DBP* 
mmHg 
Lifestyle 
Modification  Without compelling 
Indication 
With Compelling Indication 
Normal  < 120  And <80  Encourage 
Pre-hypertension  120-139 Or  80-90  Yes 
No antihypertensive 
Drug indicated 
Drug(s) for compelling indications
Stage 1 
Hypertension
140-159 Or  90-99  Yes 
Thiazide-type diuretics for most, May 
consider ACEI, ARB, BB, CCB, or 
combination 
Stage 2 
Hypertension
160 Or  100 Yes 
Two-drug combination for most (usu-
ally thiazide-type diuretic and ACEI or 
ARB or BB or CCB 
Drug(s) for the compelling indica-
tions. Other antihypertensive drugs 
(diuretics, ACEI, ARB, BB, CCB) 
as needed 
DBP, diastolic blood pressure; SBP, systolic blood pressure 
Drug abbreviations: ACEI, angiotensine converting enzyme inhibitor; ARB, angiotensin receptor blocker; BB; beta-blocker; CCB, calcium channel blocker. 
. Treatment determined by highest BP category 
 Initial combined therapy should be used cautiously in those at risk for orthostatic hypotension 
 Treat patients with chronic kidney disease or diabetes to BP goal of < 130/80 mmHg 
Fig. (3). Stroke mortality rate in each decade of age versus usual blood pressure at the start of that decade. Source: Reprinted with permission 
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  The Canadian Heart Health Survey (CHHS) showed that 
the overall prevalence of ISH was 8.1% and the prevalence 
of untreated ISH was 6.4% [17]. Figures from Australia sug-
gested an ISH prevalence of 8.6% in patient  60 years old 
[18]. Supporting data from the JNC-VII noted that although 
59% of hypertensive patients were receiving treatment, only 
34% had blood pressure levels below 140/90 [7]. 
  In the WHO report, sub optimal BP (> 115 mm Hg SBP) 
is responsible for 62% of cerebrovascular disease and 49% 
of ischemic heart disease [19]. However, the WHO guide-
lines set a lower threshold than those advocated by JNC-VII. 
Acceptance of the WHO threshold results in 60% of the 
population being classified as hypertensive [20]. Taking into 
consideration the current definition of ISH, it does not only 
become the most common subtype of hypertension world-
wide but also the most prevalent untreated hypertension 
among people over 60 years of age [21]. In a recent Euro-
pean study, the prevalence of ISH in patients over 55 years 
was found to range between 20.3% in primary care patients 
and 35% in the community, using mean values of both sys-
tolic and diastolic blood pressure [22]. The study included 
over 1,000 participants with all blood pressure measurements 
recorded in accordance with the standards of the JNC VI. In 
the years to come, the number of elderly among the popula-
tion is expected to rise rapidly and clearly ISH prevalence 
will be an even more important issue.  
Pathophysiology of ISH and its Cardiac Sequel 
  Data from clinical studies indicate that ISH is a distinct 
syndrome with pathophysiological changes different from 
those in essential hypertension [23]. The main feature of ISH 
is a decreased distensibility of the aorta and large arteries 
with subsequent cardiovascular events [24,25]. Mechanical 
changes in the arterial walls such as atherosclerosis and the 
gradual loss of aortic distensibility, occurring over the course 
of the ISH, was thought to be a natural event of the aging 
process [26]. Framingham heart study has also demonstrated 
an increase in arterial stiffness due to aging or pathology and 
a decrease in arterial distensibility [27]. Though other studies 
have questioned the reduction in distensibility as a natural 
consequence of aging [23,28], the recent Framin-gham off-
spring study involved healthy individuals demonstrated age-
related increase in aortic stiffness with little change in pe-
ripheral arteries [29]. It is not known whether the decreased 
distensibility or the elevation of systolic blood pressure oc-
cur first. Nevertheless, the elevation of SBP increases the 
sheer stress and fatigue on arterial walls, accelerating arterial 
damage, exacerbating the arterial changes and atherosclero-
sis, creating a vicious cycle of plaque formation and rupture, 
further blood vessel damage, and loss of arterial distensibil-
ity. Pathology examination of the aorta in elderly patients 
with ISH reveals thickening of the media due to the accumu-
lation of the collagenous fibers and calcium [30]. The resul-
tant decrease in the arterial compliance results in higher SBP 
and pulse-wave velocity as the large arteries become less 
able to reduce the pressure generated by the left ventricle 
(LV) by means of distension (cushion function). While in-
creases in peripheral resistance will cause elevations in DBP, 
the loss of large-artery elasticity, but not in the smaller arter-
ies (resistant arterioles) as in diastolic hypertension [31], 
leads to less blood and therefore less potential energy being 
stored for forward flow during ventricular diastole. Thus for 
a given heart rate and peripheral resistance, diastolic pressure 
is low. In addition, ISH impairs conduit artery endothelial 
function whereas diastolic hypertension induces endothelial 
dysfunction in resistance arteries in the elderly [32].  
  The heart adapts to the ensuing increase in wall tension 
by hypertrophy and increased myocardial contraction time. 
Although these adaptations seem to preserve systolic func-
tion, diastolic impairment becomes apparent as LV compli-
Fig. (4). Changes in systolic and diastolic blood pressure with age. SBP and DBP by age and race or ethnicity for men and women over 18 
years of age in the US population. Data from NHANES III, 1988 to 1991. Permission source: Roccella EJ et al. Seventh Report of the Joint 
National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood  Pressure Hypertension 2003; 42: 1206. 26 Current Cardiology Reviews, 2008, Vol. 4, No. 1 Fayad and Yang 
ance and early diastolic filling decline  [33,34]. As a result, 
ISH patients demonstrate an increase in LV mass and a high 
prevalence of LV hypertrophy (LVH) compared with age-
matched normotensive individuals [35,36]. When compared 
to diastolic hypertension, the prevalence of LVH was higher 
in ISH patients despite lower mean blood pressure [37]. 
These LV changes occur over time and usually carry prog-
nostic significance [38,39]. Studies have shown that LVH is 
associated with an increase in cardiovascular events (stroke, 
ischemic heart disease and heart failure) [39,40]. In a recent 
study on coronary blood flow in normal subjects versus pa-
tients with LVH, there was a significant reduction of the 
peak coronary flow during diastole in LVH patients [41]. In 
addition, the correlation between hypertension, LVH and left 
atrium (LA) size is well documented [42]. Data suggest that 
LA size is an important factor in the development of atrial 
fibrillation and other cardiovascular events [43,44].  
  The presence of LVH in ISH patients frequently leads to 
diastolic dysfunction (DD) [45,46]. Though DD may be seen 
in the elderly without high blood pressure or increased LV 
mass [47], a higher prevalence of DD was seen in patients 
with ISH stage 1 (systolic pressures between 140-159 mm 
Hg) without any impairment of systolic function [48]. Left 
ventricular end diastolic pressure (LVEDP) is an important 
factor that determines oxygen supply to the myocardium, as 
it is the pressure, which is exerted directly on the subendo-
cardium. The amount of flow entering the coronary circula-
tion during diastole is the result of the pressure gradient be-
tween the epicardial coronary artery and the subendocar-
dium. Elevation of the LVEDP as in DD patients can reduce 
this gradient significantly, and hence, decreasing the coro-
nary blood flow and myocardial perfusion [49]. The oxygen 
cost of “pressure work” is greater than “volume work”, with 
the area-under-the-curve for LV pressure closely correlating 
with myocardial oxygen demand [50]. In hypertensive pa-
tients, free of coronary artery stenosis, DD may be a deter-
minant in the impairment of the coronary microvascular 
vasodilation capacity or a marker of silent ischemia involv-
ing the microvascular circulation [51]. In essence, the com-
bination of lower diastolic blood pressure, LVH, LA, and 
DD in ISH may compromise subendocardial myocardial 
perfusion.
ISH and Cardiovascular Events 
  For decades, despite the focus on DBP, many investiga-
tors know that ISH is a cardiovascular risk factor, frequently 
seen in the elderly [21,52-55]. Recent studies however, have 
renewed interest in ISH and accumulating evidence warrants 
greater attention to the importance of SBP as a major factor 
for CVD.  
  In a cardiovascular health study on hypertensive predic-
tors of cardiovascular events (myocardial infarction, stroke 
and mortality), SBP was the single best predictor of cardio-
vascular events [56]. After adjusting for myocardial infarc-
tion, a one-standard deviation change in SBP, DBP, and 
pulse pressure was associated with hazard ratios (95% confi-
dence intervals) of 1.24 (1.15-1.35), 1.13 (1.04-1.22), and 
1.21 (1.12-1.31), respectively. For stroke, the hazard ratios 
(95% confidence intervals) were 1.34 (1.21-1.47) with SBP, 
1.29 (1.17-1.42) with DBP, and 1.21 (1.10-1.34) with pulse 
pressure. The study involved 5,888 participants recruited 
from four US centers aged 65 years and older. The average 
follow up in the study was 6.7 years with a linear association 
between blood pressure level and cardiovascular disease risk.  
  Further supporting data comes from the analysis of the 
Framingham 30-year study. It demonstrated that SBP is a 
strong and a consistent predictor of coronary artery disease 
over several age strata [57]. The MRFIT trial with its initial 
361,662 participants also provides evidence of the close rela-
tionship between the level of SBP and coronary heart dis-
ease. The age of the MRFIT trial participants ranged be-
tween 36-57 years old when they were first screened with 3 
successive screenings and frequent follow up [58-60]. 
  Studies from Europe have also demonstrated a positive 
continuous, graded, and independent association for both 
total (P<. 001) and cardiovascular (P< .001) mortality with 
SBP but not DBP. Blood pressure was linearly related to the 
risk of stroke in untreated patients [61] but, in patients with 
treated hypertension, the relationship of both SBP and DBP 
to stroke was J-shaped with increased risk at high and low 
levels of blood pressure [62]. The risk of first-ever stroke 
was associated with hypertension (relative risk, 1.6; 95% CI, 
1.2 to 2.0) and with isolated ISH (relative risk, 1.7; 95% CI, 
1.1 to 2.6). In a recent study this J shape pattern wasnot seen 
in general population or in individuals without chronic renal 
insufficiency  [63].  
  A study from China examined ISH, isolated diastolic 
hypertension and systolic-diastolic hypertension as predic-
tors of stroke [64]. The relative risks of stroke with the sub-
types of hypertension, compared with normotensives, were 
estimated using the Cox model. After adjustments for the 
confounders, the prevalence of hypertension was: ISH 7.1%, 
systolic-diastolic hypertension 18.4%, isolated diastolic hy-
pertension 6.7%, and controlled hypertension 3.9%. The 
follow up study included a total of 233,437 patients. There 
were 1,107 stroke (614 ischemic and 451 hemorrhagic events 
and 42 unclassified). The hazard ratio and 95% CI was 2.96 
(2.49 to 3.52) for all stroke. Both ISH and isolated diastolic 
hypertension were independent predictors of stroke. Patients 
with systolic-diastolic hypertension however, were at the 
highest risk of stroke and should be treated aggressively.  
  Beside its cardiovascular risk, high blood pressure is re-
garded as a major risk factor for the development of renal 
insufficiency [65]. When both SBP and DBP variables were 
considered, the estimated risk of chronic renal insufficiency 
was higher with elevated SBP [66].  
Treatment of ISH and the reduction of Cardiovascular 
Events 
  Treatment to reduce elevated systolic blood pressure to 
less than 140 mmHg has been shown to reduce significantly 
the risk of cardiovascular events [67-70]. The Systolic Hy-
pertension in the Elderly program (SHEP) [67] was the first 
large-scale trial to document a benefit from treatment of ISH. 
The 4,736 patients were enrolled in a double blind, random-
ized, placebo-controlled study. Patients in this trial were 
treated with chlorthilidone ± atenolol to achieve SBP < 160 
mmHg. The primary end point was the number of fatal and 
nonfatal strokes with the cardiac events as the secondary end Is Peri-Operative Isolated Systolic Hypertension  Current Cardiology Reviews, 2008, Vol. 4, No. 1    27
points. Though the definition of ISH in the trial was out-
dated, there was a 36% reduction in stroke risk (P= <0.003), 
25% reduction in coronary heart disease (P=<0.05) and 32% 
fall in total cardiovascular disease evens (P=<0.05) in the 
active treatment group compared to the placebo group.  
  Encouraging results were also obtained from the Systolic 
Hypertension in Europe (Syst-Euro) trial [68,71,72]. In the 
trial, 4,695 patients were randomized to receive the long-
acting dihydropyridine calcium channel blocker nitrendipine 
or a placebo. If BP was not controlled, enalapril, hydrochlor-
thiazide, or both were added. The primary end point was 
fatal and nonfatal strokes. Similar results to the SHEP were 
obtained. There was a 43% (P= 0.003) reduction of fatal or 
non-fatal stroke in patients treated actively to achieve SBP < 
150 mmHg. As in the SHEP study, total mortality was not 
reduced significantly by active treatment. The extended fol-
low-up study (Syst-Eur2) [73] of the trial obtained similar 
results.  
  A reduction in the incidence of stroke and other cardio-
vascular complications was also achieved in the Systolic 
hypertension in China (Syst-China) [74] and the Shanghai 
Trial of Nifedipine in the Elderly (STONE) in the treatment 
groups [75]. The Syst-China follow up study did not demon-
strate a significant overall influence on the active treatment 
group but there were clear benefits of treatment in diabetic 
and non-smoker patients [76]. Further, the meta-analysis of 
ISH outcome trials showed that the treatment of ISH confers 
a protective effect against stroke and coronary heart disease 
risk [77].  
  Different drug therapies have been suggested to treat 
systolic blood pressure. These included the use of diuretics, 
beta-blockers, calcium channel blockers and angiotensin 
converting enzyme inhibitors (ACEI). The JNC-VII (Table 
1) has also recommended the use of a single antihypertensive 
therapy or a combination of two or more for stage 1 and 
stage 2 hypertension. The choice of the antihypertensive 
usually takes into consideration the type and subtype of hy-
pertension, the severity, and the co-morbidities. In addition, 
when prescribing an antihypertensive medication, clinicians 
should also be aware of the patient’s compliance to treat-
ment. 
  A recent study suggested that caution should be exercised 
on lowering blood pressure less than 140/90 in patients over 
80 years old [78]. In another study, lowering DBP (< 65-70 
mmHg) in the course of treating ISH may be associated with 
an increase risk of stroke and other cardiovascular events 
[69]. 
II) ISOLATED SYSTOLIC HYPERTENSION AS A 
PERIOPERATIVE CARDIOVASCULAR RISK FAC-
TOR 
Recognition of the Problem 
  Sprague, in 1929, was the first to examine the relation-
ship between hypertension and perioperative cardiac risks. In 
his report, he described a series of 75 hypertensive patients 
of whom 1/3 died in the perioperative period [79]. Prys-
Roberts conducted a series of “studies of anesthesia in rela-
tion to hypertension” [80-83]. Intraoperative hemodynamic 
instability was found to be the major cardiovascular event in 
uncontrolled hypertensive patients. The first of his studies 
examined 29 patients undergoing elective non-cardiac sur-
gery [80]: there were 7 normotensive, 7 untreated and 15 
patients on antihypertensive medications. Labile BP associ-
ated with myocardial ischemia was noted during induction of 
anesthesia and during the intraoperative course in the un-
treated group. The subsequent study with 36 hypertensive 
patients assessed the electrocardiographic and hemodynamic 
responses to induction of anesthesia, laryngoscopy and en-
dotracheal intubation [81]. There were 16 untreated patients 
and 20 on antihypertensive medications. Treated and un-
treated patients were divided into 5 groups based on the type 
of anesthesia induction (thiopentone, neuroleptanalgesia, 
propanidid, diazepam and methohexitone). Surprisingly, the 
study found that patients on antihypertensive therapy with 
well-controlled blood pressure were equally prone to develop 
hemodynamic instability and myocardial ischemia. However, 
close analysis of the preoperative BP values, using the JNC-
VII definition of hypertension, identifies 13 ISH patients 
who were considered controlled hypertensive or normoten-
sive patients. The conclusion was that patients with uncon-
trolled or poorly controlled hypertension, especially with 
DBP above 110 mmHg, should not undergo elective surgery 
until their blood pressure is controlled. The conclusion was 
not based on hard outcomes in perioperative cardiac compli-
cations but on the perioperative hemodynamic instability. 
Goldman and Caldera, in 1979, compared 431 normotensive 
patients with 248 hypertensive patients [84]. There was a 
higher incidence of cardiovascular complications in the hy-
pertensive group but it didn’t reach statistical significance. In 
essence, there was no indication of an increased risk of car-
diovascular complications in the perioperative period, re-
gardless of DBP. There was no reference to ISH. Other stud-
ies on perioperative risk factors supported the findings by 
Goldman and concluded that hypertension alone was a minor 
risk factor [85-87].  
  In a multicenter prospective study of 17,201 patients un-
dergoing elective surgery, Forrest et al. [88] found 17 sig-
nificant predictors of severe adverse cardiovascular events 
(deaths, cardiovascular outcome and respiratory outcome). 
Preoperative hypertension was found to be associated with 
an increased risk of perioperative bradycardia, tachycardia 
and hypertension. In another, 17,638 consecutive day-case 
surgical patients were examined to develop mathematical 
models to estimate the risk of perioperative adverse events in 
patients with pre-existing conditions [89]. Hypertension was 
found to predict the occurrence of any intraoperative event 
and intraoperative cardiovascular events. Shackelford et al.
[90] evaluated Goldman and New York Heart Association 
cardiac risk index values as risk factors for perioperative 
cardiac morbidity in patients undergoing major vaginal sur-
gery. It was a retrospective analysis of 406 patients with 8 
patients having perioperative cardiac morbidity. The Gold-
man cardiac risk index and the New York Heart Association 
functional classification of heart disease were not significant 
indicators of perioperative cardiac morbidity in this group of 
patients. However, hypertension and ischemic heart disease 
were found to be risk factors for perioperative cardiac mor-
bidity in a postmenopausal subgroup of these patients. None 
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  Although well conducted at the time, we believe that 
these early studies failed to recognize ISH as a perioperative 
risk factor for the following reasons. First, ISH was recog-
nized as a cardiovascular risk factor only in recent years. For 
decades, ISH was not deemed to be strongly associated with 
the same sequelae as in diastolic or combined hypertension 
[67,91,92]. Hence, the focus for perioperative studies has 
been mainly on DBP. Second, the definition of ISH and the 
emphasis on its treatment were established only recently at 
the JNC VI [93]. Third, many patients with high systolic 
blood pressure were not considered previously to be hyper-
tensive as the earlier definition of ISH, utilized in most of the 
literature, was SBP > 160 mmHg. This led to a significant 
proportion of ISH patients being missed from the old pe-
rioperative hypertensive studies. Fourth, the sample sizes of 
previous perioperative hypertensive studies were too small to 
draw firm conclusions on perioperative hard outcomes with-
out type II errors.  
 Howell  et al. examined the role of a number of risk fac-
tors in the development of silent ischemia after general anes-
thesia for general and vascular surgery in 183 patients [94]. 
Patients were monitored pre- and postoperatively for ische-
mia using a Holter electrocardiography monitor. A history of 
hypertension, indicated by treatment with antihypertensive 
drugs, was associated with increased risk (odds ratio: 2.58, 
95% confidence intervals: 1.12-5.96). A linear trend was 
found for risk associated with increasing admission systolic 
blood pressure (odds ratio: 1.20 for each 10-mmHg increase 
in systolic pressure, 95% confidence intervals: 1.01-1.42). 
However, the study did not specifically examined ISH as a 
perioperative predictor.  
  Also, Howell and co-workers examined the association 
between perioperative hypertension and cardiovascular com-
plications including clinical trials, systematic reviews and 
meta-analysis [95-98]. There was an increase in the inci-
dence of postoperative myocardial ischemia and an increase 
in cardiovascular death within 30 days of elective surgery  
[95-97]. The recent meta-analysis of 30 observational studies 
involving 13,671 patients [99] has looked at hypertension 
and major perioperative cardiovascular outcomes. Major 
outcome complications were identified as cardiovascular 
death, myocardial infarction, new or more severe angina, 
heart failure, life threatening arrhythmias, and cerebrovascu-
lar accident. It demonstrated an odds ratio of 1.35 (1.17 – 
1.56), which is not clinically significant. The study repre-
sents the most complete summation of evidence to-date; 
nevertheless, the definition for hypertension used by most of 
the studies in the meta-analysis predated the definition for 
ISH. The authors also found significant heterogeneity in the 
meta-analysis and attempted to isolate the source with a 
number of sensitivity analyses without success.  
  The only study looking at the association between ISH 
and postoperative cardiovascular events was carried out in 
the open-heart surgery patients [100]. It was a multicenter 
prospective observational study involved 2417 patients 
scheduled for elective CABG. The postoperative adverse 
outcome variables were congestive heart failure, renal insuf-
ficiency, central nervous system dysfunction and death. Of 
the 2069 that qualified for analysis, 612 had ISH. Among the 
612 patients with systolic hypertension 52% had SBP be-
tween 140-150 mmHg. Most patients were receiving some 
type of antihypertensive medications and their mean age was 
65 years with Caucasian majority. ISH combined with other 
risked factor was associated with 40% increase in likelihood 
of perioperative cardiovascular morbidity. This increase re-
mains present regardless of antihypertensive medications, 
anesthetic techniques, and other perioperative cardiovascular 
risk factors. The prediction power of ISH was a 30% in-
crease in the likelihood of an adverse outcome (odd ratio 1.3; 
95% CI, 1.1-1.6). This study obviously provides evidence 
that ISH increases the risk of perioperative cardiovascular 
complications in patients undergoing CABG surgery. How-
ever, a limitation of this study was reliance on a single pre-
operative measurement of blood pressure.  
  Although the ACC/AHA guidelines do not identify hy-
pertension as an independent risk factor for perioperative 
cardiovascular complications [80], it reflects more of the 
limitations of existing studies. 
Prevalence of the Perioperative ISH 
  The prevalence of perioperative ISH in non-cardiac sur-
gery remains unclear. While it is unknown if the same per-
centage of ISH in the community presents for surgery, the 
proportion of untreated perioperative ISH is also unknown. 
In patients undergoing coronary artery bypass grafting 
(CABG), the prevalence of perioperative ISH was found to 
be 29.6% [100]. ISH is particularly prevalent in elderly pa-
tients and with the aging population, we will experience an 
increase in the prevalence [101]. By 2030, it is estimated that 
20% of the population will be aged 65 and older with a sig-
nificant increase in the number of surgical procedures among 
the elderly [102,103].  
Pathophysiology of ISH and the Perioperative Period 
  A study on 118 patients with uncomplicated mild hyper-
tension using echocardiography found that concentric LV 
geometry was found mainly in untreated patients. This re-
sulted in the identification of a high-risk subgroup with con-
centric remodeling, which had not been recognized or treated 
[104]. Although conducted in a non-surgical setting, such a 
study highlights the fact that physiological and anatomical 
adaptations may be more complex than merely accepting all 
uncomplicated hypertensive patients being the same. In the 
perioperative period after major non-cardiac surgery, the 
physiological and stress hormonal responses add another 
layer of complexity.  
  The development of LVH and DD are common in ISH 
patients [37,45]. Diastolic dysfunction in the aging heart is 
increasingly recognized as a cause of heart failure  [105-
108]. History of heart failure is an important predictor post-
operative adverse cardiac outcome and in hospital mortality 
in the elderly  [109,110]. Previous studies have shown that 
the pre-operative DD is present in 30 – 70% of cardiac surgi-
cal patients and has been associated with difficult weaning 
from cardiopulmonary bypass, the need for more frequent 
pharmacologicalsupport,and increased morbidity  [111,112]. 
In addition, preoperative DD was found to be a significant 
marker of in-hospital mortality after cardiac surgery and is 
independent of systolic function or the type of cardiac proce-
dure [113]. Intraoperative acute DD is a new entity, which Is Peri-Operative Isolated Systolic Hypertension  Current Cardiology Reviews, 2008, Vol. 4, No. 1    29
was observed by our research group during thoracoabdomi-
nal aortic aneurysm surgery [114]. In that study, postopera-
tive myocardial infarction was significantly higher in pa-
tients who developed intraoperative acute DD. Numerous 
studies have examined diastolic dysfunction in the non-
surgical setting and found a strong evidence to show that 
abnormalities of diastolic filling can determine the clinical 
status and the prognosis of the patients [115-117]. 
  During the perioperative period, stress hormones and 
catecholamine surges are well reported [118-121]. Sympa-
thetic activation during the induction of anesthesia can cause 
the blood pressure to rise by 20 - 30 mmHg and the heart rate 
to increase by 15 - 20 beats per minute in normotensive indi-
viduals. These responses are exacerbated in hypertensive 
patients in whom the SBP can increase by 90 mmHg and 
heart rate by 40 beats per minute [122]. Following intubation 
and maintenance of anesthesia, the mean arterial pressure 
tends to fall due to a variety of factors. Some of these factors 
include inhibition of the sympathetic nervous system, and 
loss of the baro-receptor reflex control of blood pressure. 
Patients with preexisting hypertension are more likely to 
experience intraoperative labile blood pressure [84]. Blood 
pressure and heart rate increase during emergence from anes-
thesia and during the immediate postoperative period. Hy-
pertensive individuals in particular may experience signifi-
cant increases in these parameters [123]. These rapid hemo-
dynamic changes in the presence of ISH exacerbate any po-
tential imbalance of myocardial oxygen supply and demand 
[124]. As mentioned previously, the presence of LVH and 
DD secondary to ISH may compromise coronary perfusion 
by decreasing the difference between DBP and LVEDP.  
Perioperative ISH as a Cardiac Risk Factor in Low-Risk 
Patients 
  Perioperative cardiac complications frequently compli-
cate non-cardiac surgery patients. In 1990, perioperative 
cardiac complications affected up to 1 million patients and 
incurred an estimated cost of US$20 billion [125]. When a 
cardiac complication occurs, the length of stay on average is 
increased by 11 days [126]. With the aging population, the 
disease burden from cardiac complications is expected to 
increase. Many of the perioperative studies focused on de-
veloping scores to identify patients that are at high risk of 
cardiac complications preoperatively.  
  A recent database study of over 700,000 patients showed 
that -blockers in Revised Cardiac Risk Index (RCRI) Score 
0 or 1 may increase all-cause mortality [127]. Of the de-
nominator, RCRI Score 0 and 1 comprised 569,581 of the 
663,635 eligible patients while RCRI Score  3 comprised 
17,071, with RCRI Score 2 adding another 76,983 patients. 
Hence, RCRI Score  2 represented <15% of the total popu-
lation. Of the total mortality, however, 8,443 were from 
RCRI Score 0 and 1 patients; only 545 were from RCRI 
Score  3 and 1,793 were RCRI Score 2 patients. The bulk 
of the burden of illness, in terms of mortality, is in the “low 
risk” patients by the sheer size of the denominator. This 
highlights that the mortality occurred in low risk patients 
with the majority of death occurred in “low risk” group. This 
may be due to low risk patients having idiosyncratic events 
perioperatively, or due to risk factors that are not currently 
understood, or both.  
Perioperative Management of ISH 
  The aim of preoperative assessment is to evaluate and 
optimize the patient’s condition perioperatively thus mini-
mizing adverse events or last-minute surgery cancellation.
Evaluation of ISH patients presenting for surgery should 
follow the standard preoperative steps in obtaining medical 
history, physical examination and investigations. Acute onset 
of sever hypertension raises the suspicion of a secondary 
form of ISH. Patients with a history of cardiac, vascular or 
renal disease should be ensured about the level of their hy-
pertension control. Individuals may have undiagnosed ISH 
for years without having had their blood pressure checked. 
Therefore, a careful history of end organ damage should be 
obtained. History of other cardiac risk factors including hy-
percholesterolemia, diabetes mellitus, tobacco, and family 
history of coronary artery disease should be obtained. If a 
secondary form of ISH is suspected, details of possible 
causes should be explored including renal diseases, pheo-
chromocytoma, hyperthyroidism, and coarctation of aorta. 
An accurate measurement of blood pressure with a proper 
cuff size is crucial. The patient should rest quietly in the pre-
assessment unit for at least five minutes before the blood 
pressure measurement. Cardiovascular examination should 
focus on listening for S3, S4 and murmurs of coexisting 
valvular disease. Peripheral pulses should also be palpated to 
assess for vascular disease. Also, ausculatation for renal ar-
tery bruit over the upper abdomen: the presence of a unilat-
eral bruit with both a systolic and diastolic component sug-
gests renal artery stenosis. A funduscopic evaluation of the 
eyes should be performed to detect any evidence of hyper-
tensive retinopathy. Investigations in relation to ISH should 
be directed toward assessing the extent of the end organ 
damage.  
  Currently, there is no evidence to identify stage 1 dia-
stolic hypertension (DBP >90 - < 110 mmHg) as a predictor 
of adverse perioperative outcomes [88,89]. When DBP is 
110mmHg, the traditional approach is to defer elective sur-
gery [128]. This practice is not based on level 1 evidence, 
but solely on the perception that such elevated pressure is 
associated with increased perioperative risk [129].  
  In patients with ISH undergoing CABG, there is evidence 
that the incidence of perioperative cardiovascular complica-
tions is increased [129]. Also, the incidence of postoperative 
myocardial ischemia has been shown to increase with in-
creasing admission SBP [94]. This may be of concern since 
the association between postoperative myocardial ischemia 
and postoperative ischemic cardiac events has been shown to 
be significant [130-132]. Induction of anesthesia in elderly 
patients with uncontrolled SBP showed substantial decrease 
of systolic pressure and stroke volume with marked vaso-
pressor response to noxious stimuli [124]. Tamborini et al.
[133], noted not only the significant reduction of systemic 
blood pressure in the uncontrolled ISH but also a decrease in 
the coronary blood flow during induction of anesthesia. In 
addition, high blood pressure was found to be a major risk 
factor for coronary artery disease [67], congestive heart fail-
ure [134], renal, and cerebrovascular diseases [135]. Any of 30 Current Cardiology Reviews, 2008, Vol. 4, No. 1 Fayad and Yang 
these factors increase the likelihood of perioperative myo-
cardial infarction or death [136]. In the absence of strong 
evidence, individual physicians would have to make their 
own decisions regarding ISH and the level SBP to warrant 
surgical cancellation. Nevertheless, it seems appropriate to 
defer elective surgery where possible in patients with stage 2 
ISH (SBP  180), especially if there is evidence of target 
organ damage.  
CONCLUSION 
  In the community, ISH is the most prevalent subtype of 
hypertension and is a significant predictor for cardiovascular 
complications. Nevertheless, it is not recognized as a signifi-
cant cardiac risk factor in the surgical setting. A number of 
reasons may explain why ISH is an unrecognized cardiovas-
cular risk factor in the perioperative period. In addition, 
pathophysiological changes such as LVH and diastolic dys-
function as a result of ISH, in conjunction with the sympa-
thetic and stress hormonal surges at the time of anesthesia 
emergence as well as during the postoperative period, pro-
vide the rationale that perioperative ISH deserves further 
studies. 
  Information emerging from a large database suggested 
that majority of the perioperative mortalities occurred in 
low-risk groups. This attracted and will attract the attentions 
of clinical investigators to look at possible under diagnosed 
risk factors. We believe that ISH is under diagnosed risk 
factors. Because of the lack of perioperative ISH clinical 
trials, we were not able to conduct a systematic review or a 
meta-analysis of perioperative ISH at this stage. 
  Until we have the complete necessary data, we will con-
tinue using best practice based on the available data. The 
current work of the PROMISE study will be the stepping-
stone toward answering the question; is the perioperative 
ISH a cardiac risk factor? 
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